This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment.
From this week's @JAMAOnc: "Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors". This is largest evaluation of this topic, providing details of how , when, from what regimens, & how often fatalities from immunotherapy occur. Worth knowing.
ja.ma/2xkpTBwpic.twitter.com/wEgEr1I7Jf
This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment. Learn more: ja.ma/2rkiVto #ASH18 pic.twitter.com/npZxrffara
Great work from @VUMChealth looking @WHO pharmacovigilance data to study fatal immune-related AEs @CardioOncology, rare but important to be aware.
At #ASH18? Visit Booth 2805 today before 5 p.m. to get a copy of "Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis" ja.ma/2FGP5t1pic.twitter.com/7nDzKgv4Ry
Fatal toxicity with immune checkpoint inhibitors is not common but does occur; vigilance remains key; most occur in the early period (median 40 days with single agent; 14 days with combination) ja.ma/2xhs3lo #bladdercancer #immunotherapy @B_C_A_N
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
A Systematic Review and Meta-analysis. A broad range of regimen-specific toxic effects caused fatalities in 0.3% to 1.3% of treated patients. JAMA
Mechanisms of fatal Immune checkpoint inhibitor (ICI) events: large study shows early onset of death with varied causes. Risk varies by therapeutic regimen. Rare events. Important clinical knowledge. #mmsm @theMMRF @IMFmyeloma
Important and thorough analysis on the fatalities attributed to I/O treatments and combinations. Almost half of Rx fatalities occur within 3 months - has anyone found some combination of host genetics and immune status to identify pts at greatest risk?